Several members of the advisory group said the treatment, which consists of 40 pills taken over 5 days, should be used in older patients or those with significant underlying medical conditions that put them at high-risk for COVID-19 complications.
The drug requires final approval from both the FDA and the Centers for Disease Control and Prevention (CDC) before it will be widely available on an emergency use basis. The FDA typically follows the committee’s recommendations.
Omicron still not detected in US
Despite extensive genomic sequencing, the CDC and the White House today said the Omicron (B.1.1.529) COVID-19 variant has yet to be detected in the United States.
“This virus is unpredictable, and we must be ready to be proactive,” said CDC Director Rochellle Walensky, MD, MPH. Walensky said the nation was in a good position to tackle Omicron, which has several mutations from the original strain of the virus, as well as the Delta (B1617.2) strain.
Source: FDA panel recommends molnupiravir, first pill for COVID-19 | CIDRAP




You must be logged in to post a comment.